Who is affected by this change?

This affects Humana Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Jan 1, 2022.

Which billing codes are affected?

The following codes are affected: J8521.

Back to dashboard

Medicare AdvantagePrior AuthMedium impact

Xeloda (capecitabine) (Revised)

Q: What do I need to do?

Immediately: Billing and prior authorization teams must implement Humana Medicare Advantage prior authorization requirements for all Xeloda (capecitabine) claims. For each request, verify: (1) the member's cancer diagnosis matches one of the 11 approved indications (anal, colorectal, CNS, esophageal, gastric, head/neck, breast, hepatobiliary, neuroendocrine pancreatic, ovarian, or pancreatic adenocarcinoma); (2) the specific clinical criteria for that indication are met (e.g., Stage II/III colorectal cancer, recurrent/metastatic breast cancer, etc.); (3) the member does NOT have severe renal impairment (CrCl <30 mL/min). Update prior authorization workflows in your billing system to include these specific clinical criteria as mandatory fields. Add a checklist to provider order forms requesting documentation of cancer stage, prior treatment history, HER2 status (for breast cancer), and renal function. Flag all claims for members with CrCl <30 mL/min as non-approvable and communicate denial to providers immediately. Train billing staff on the nine distinct approval pathways within the breast cancer indication (HER2-negative, HER2-positive combinations, single-agent options). Failure to obtain prior authorization will result in claim denials.

Humana·Oncology, Hematology·Medicare Advantage

Effective date

Jan 1, 2022

We identified it

Jun 25, 2026

Days to comply

—

Summary

Humana Medicare Advantage revised its Xeloda (capecitabine) pharmacy coverage policy on December 17, 2025, establishing prior authorization requirements across 11 cancer indications with specific clinical criteria and a universal exclusion for severe renal impairment (creatinine clearance <30 mL/min). This is a maintenance revision that clarifies and consolidates coverage criteria for this chemotherapy agent.

Action Required

Action needed

Immediately: Billing and prior authorization teams must implement Humana Medicare Advantage prior authorization requirements for all Xeloda (capecitabine) claims. For each request, verify: (1) the member's cancer diagnosis matches one of the 11 approved indications (anal, colorectal, CNS, esophageal, gastric, head/neck, breast, hepatobiliary, neuroendocrine pancreatic, ovarian, or pancreatic adenocarcinoma); (2) the specific clinical criteria for that indication are met (e.g., Stage II/III colorectal cancer, recurrent/metastatic breast cancer, etc.); (3) the member does NOT have severe renal impairment (CrCl <30 mL/min). Update prior authorization workflows in your billing system to include these specific clinical criteria as mandatory fields. Add a checklist to provider order forms requesting documentation of cancer stage, prior treatment history, HER2 status (for breast cancer), and renal function. Flag all claims for members with CrCl <30 mL/min as non-approvable and communicate denial to providers immediately. Train billing staff on the nine distinct approval pathways within the breast cancer indication (HER2-negative, HER2-positive combinations, single-agent options). Failure to obtain prior authorization will result in claim denials.

Affected Billing Codes

J8521

Related policy hubs

Humana policies Oncology Hematology Code J8521